Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03579641 · ClinicalTrials.gov registry record
Precision Event Monitoring for Patients With Heart Failure Using HeartLogic
A clinical trial, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 2,184
- Enrollment target
NCT03579641 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 2,184 participants.
The verdict
NCT03579641 has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 2,184 participants
- Enrollment target
Study Summary
The goal of the PREEMPT-HF study is to collect device and clinical event data to evaluate extended applications of the HeartLogic Heart Failure Diagnostic (HeartLogic) in a broad spectrum of heart failure patients with an implantable cardioverter defibrillator or cardiac resynchronization therapy defibrillator. There are no primary safety and/or efficacy endpoints for this study. Heart failure is a complex clinical syndrome with high morbidity, mortality, and economic burden. Chronic Heart Failure is persistent, gradually progressive, and punctuated by episodes of acute worsening leading to hospitalizations. Therefore, there remains an unmet clinical need to slow the progression of Heart Failure and prevent hospitalizations. HeartLogic, available in Boston Scientific cardiac resynchronization therapy devices and defibrillators, combines novel sensor parameters such as heart sounds and respiration with other measurements like thoracic impedance, heart rate, and activity into a HeartLogic Index for the early detection of worsening Heart Failure. However, there is limited data on the association of HeartLogic with the risk of Hear Failure readmissions and tachyarrhythmias, or for phenotyping the broad spectrum of Heart Failure patients.
Interventions
- DEVICE HeartLogic Sensors
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,184 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2021-10-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03579641
The ClinicalTrials.gov registry entry for NCT03579641 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,184 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HeartLogic Sensors is the first listed.
NCT03579641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03579641 about?
NCT03579641 is a clinical study titled "Precision Event Monitoring for Patients With Heart Failure Using HeartLogic". The goal of the PREEMPT-HF study is to collect device and clinical event data to evaluate extended applications of the HeartLogic Heart Failure Diagnostic (HeartLogic) in a broad spectrum of heart failure patients with an implantable cardioverter defibrillator or cardiac resynchronization therapy de...
What is the current status of trial NCT03579641?
This trial is currently completed. The enrollment target is 2,184 participants. The study started on 2018-06-01. Estimated completion is 2021-10-29.
What interventions are being tested in trial NCT03579641?
The interventions under investigation include: HeartLogic Sensors (DEVICE).
Who is sponsoring clinical trial NCT03579641?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.